435 related articles for article (PubMed ID: 34512641)
1. Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.
Chandrasekaran S; Funk CR; Kleber T; Paulos CM; Shanmugam M; Waller EK
Front Immunol; 2021; 12():718621. PubMed ID: 34512641
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8
Dwyer CJ; Arhontoulis DC; Rangel Rivera GO; Knochelmann HM; Smith AS; Wyatt MM; Rubinstein MP; Atkinson C; Thaxton JE; Neskey DM; Paulos CM
Eur J Immunol; 2020 Sep; 50(9):1386-1399. PubMed ID: 32383488
[TBL] [Abstract][Full Text] [Related]
3. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
Cao L; Dai C; Qin R; Guo Y; Liu J
Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
[No Abstract] [Full Text] [Related]
4. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.
Lim EL; Okkenhaug K
Immunology; 2019 Jul; 157(3):210-218. PubMed ID: 31107985
[TBL] [Abstract][Full Text] [Related]
5. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
Han MG; Jang BS; Kang MH; Na D; Kim IA
Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
[TBL] [Abstract][Full Text] [Related]
6. Regulation of T cell alloimmunity by PI3Kγ and PI3Kδ.
Uehara M; McGrath MM; Ohori S; Solhjou Z; Banouni N; Routray S; Evans C; DiNitto JP; Elkhal A; Turka LA; Strom TB; Tullius SG; Winkler DG; Azzi J; Abdi R
Nat Commun; 2017 Oct; 8(1):951. PubMed ID: 29038423
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
8. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
[TBL] [Abstract][Full Text] [Related]
9. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
[TBL] [Abstract][Full Text] [Related]
10. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models.
Iannello A; Vitale N; Coma S; Arruga F; Chadburn A; Di Napoli A; Laudanna C; Allan JN; Furman RR; Pachter JA; Deaglio S; Vaisitti T
Blood; 2021 Jun; 137(24):3378-3389. PubMed ID: 33786583
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.
Zhang Z; Liu J; Wang Y; Tan X; Zhao W; Xing X; Qiu Y; Wang R; Jin M; Fan G; Zhang P; Zhong Y; Kong D
FASEB J; 2018 Nov; 32(11):5967-5975. PubMed ID: 29792732
[TBL] [Abstract][Full Text] [Related]
12. PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8
Carnevalli LS; Sinclair C; Taylor MA; Gutierrez PM; Langdon S; Coenen-Stass AML; Mooney L; Hughes A; Jarvis L; Staniszewska A; Crafter C; Sidders B; Hardaker E; Hudson K; Barry ST
J Immunother Cancer; 2018 Dec; 6(1):158. PubMed ID: 30587236
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by
Abu Eid R; Ahmad S; Lin Y; Webb M; Berrong Z; Shrimali R; Kumai T; Ananth S; Rodriguez PC; Celis E; Janik J; Mkrtichyan M; Khleif SN
Cancer Res; 2017 Aug; 77(15):4135-4145. PubMed ID: 28615225
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation.
Capsomidis A; Benthall G; Van Acker HH; Fisher J; Kramer AM; Abeln Z; Majani Y; Gileadi T; Wallace R; Gustafsson K; Flutter B; Anderson J
Mol Ther; 2018 Feb; 26(2):354-365. PubMed ID: 29310916
[TBL] [Abstract][Full Text] [Related]
15. Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy.
Kent A; Longino NV; Christians A; Davila E
Front Immunol; 2021; 12():658611. PubMed ID: 34012443
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.
Klebanoff CA; Crompton JG; Leonardi AJ; Yamamoto TN; Chandran SS; Eil RL; Sukumar M; Vodnala SK; Hu J; Ji Y; Clever D; Black MA; Gurusamy D; Kruhlak MJ; Jin P; Stroncek DF; Gattinoni L; Feldman SA; Restifo NP
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212954
[TBL] [Abstract][Full Text] [Related]
17. Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms.
Blanco B; Herrero-Sánchez MC; Rodríguez-Serrano C; Sánchez-Barba M; Del Cañizo MC
Immunol Res; 2015 Jun; 62(2):175-88. PubMed ID: 25869396
[TBL] [Abstract][Full Text] [Related]
18. Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade.
Peranzoni E; Ingangi V; Masetto E; Pinton L; Marigo I
Front Immunol; 2020; 11():1590. PubMed ID: 32793228
[TBL] [Abstract][Full Text] [Related]
19. Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.
Stark AK; Davenport ECM; Patton DT; Scudamore CL; Vanhaesebroeck B; Veldhoen M; Garden OA; Okkenhaug K
J Immunol; 2020 Jul; 205(1):78-89. PubMed ID: 32414808
[TBL] [Abstract][Full Text] [Related]
20. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
